Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors

Veronika Mamaeva¹–³, Rasmus Niemi¹,², Michaela Beck⁴, Ezgi Özliseli¹,⁵, Diti Desai⁵, Sebastian Landor¹,²,⁶, Tove Gronroos⁷,⁸, Paulliina Kronqvist⁹, Ina KN Pettersen¹⁰, Emmet McCormack³,¹¹, Jessica M Rosenholm⁵, Mika Linden⁴ and Cecilia Sahlgren¹,²,¹²

Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We demonstrated that enhanced Notch signaling in breast cancer promotes self-renewal of CSCs that display high glycolytic activity and aggressive hormone-independent tumor growth in vivo. We took advantage of the glycolytic phenotype and the dependence on Notch activity of the CSCs and designed nanoparticles to target the CSCs. Mesoporous silica nanoparticles were functionalized with glucose moieties and loaded with a γ-secretase inhibitor, a potent interceptor of Notch signaling. Cancer cells and CSCs in vitro and in vivo efficiently internalized these particles, and particle uptake correlated with the glycolytic profile of the cells. Nanoparticle treatment of breast cancer transplants on chick embryo chorioallantoic membranes efficiently reduced the cancer stem cell population of the tumor. Our data reveal that specific CSC characteristics can be utilized in nanoparticle design to improve CSC-targeted drug delivery and therapy.

Received 16 December 2015; accepted 12 February 2016; advance online publication 29 March 2016. doi:10.1038/mt.2016.42

INTRODUCTION

Cancer stem cells (CSC) or “tumor-initiating cells” have been identified in various cancers including breast, colon, hematopoietic, and brain cancer.¹–⁵ The CSC population is not only important for tumor initiation, but it is also linked to metastasis, therapy resistance, and recurrence.⁶ Approaches to target the CSC population can enhance the success of conventional therapies and change the outcomes of treatments. Detailed understanding of the biology of cancer stem cell survival and resistance, and the discovery of specific characteristics of CSCs will open up new possibilities for therapeutic intervention.⁷–⁹

Signaling pathways that are critical for stem cell function during development, such as the Wnt, Hedgehog, and Notch pathways are often deregulated in cancers, and promote survival and self-renewal of CSCs. Of these pathways, oncogenic Notch mutations occur in lymphoblastic leukemias, as well as in a variety of solid tumors including breast and non-small-cell lung cancer, colon, and prostate.¹⁰,¹¹ In breast cancer cells, Notch is linked to aggressive metastatic growth and therapy resistance.¹²–¹⁷ Notch signaling has been implicated to regulate the CSC population in several forms of cancer, where it has been shown to be critical for maintenance and self-renewal of CSCs.¹⁸–²² Notch-targeted therapy is thus an interesting treatment option and several clinical trials have been launched to test efficacy and safety of Notch inhibitors in cancer.¹³,²³,²⁴ Despite the availability of efficient Notch inhibitors such as γ-secretase inhibitors (GSIs), peptides, antibodies or probodies, Notch-related treatments are currently prevented by side effects, due to the requirement for Notch signaling in most tissues.²⁵,²⁶ GSI treatment induces diarrhea and suppression of lymphopoiesis.²⁷,²⁸ Antibody-based targeting of Notch ligands is associated with induction of vascular tumors in mice²⁸ and a variety of side effects including headache, hypertension, fatigue, right, and left ventricular dysfunction in patients in clinical trials.²⁹ Therefore, clinically efficient suppression of Notch activity requires more targeted delivery strategies, and efficient delivery to CSCs to target Notch signaling in this population.

Nanotechnology has been promoted as the technology for targeted drug delivery to overcome problems with poor bioavailability, efficacy, and adverse side effects, and has recently been proposed as a candidate for CSC-targeted cancer therapeutics.²⁹–³¹ Data gained over the last decade demonstrate successful therapeutic action of various nanocarriers both in vivo in preclinical models and in clinical tests.³²–³⁵ Among nanomaterials, we and others have recently demonstrated mesoporous silica particles (MSNs) to be highly versatile and efficient drug carriers in both conventional and novel cancer therapies.³⁶–³⁷ MSNs can carry a high payload of hydrophobic drugs, such as GSIs.³⁸–⁴¹ We have previously shown successful breast tumor targeting of MSNs, and demonstrated that

¹Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland; ²Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland; ³Department of Clinical Science, University of Bergen, Bergen, Norway; ⁴Inorganic Chemistry II, Ulm University, Ulm, Germany; ⁵Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland; ⁶Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; ⁷Turku PET Centre, University of Turku, Turku, Finland; ⁸Mediticy Research Laboratories, University of Turku, Turku, Finland; ⁹Department of Pathology, University of Turku, Turku, Finland; ¹⁰Department of Biomedicine, University of Bergen, Bergen, Norway; ¹¹Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway; ¹²Department of Biomedical Engineering, Technical University of Eindhoven, Institute for Complex Molecular Systems, Eindhoven, the Netherlands
the carrier is suitable for intravenous, local and oral administration, and that it localizes to tumor tissue, and is biodegradable and eliminated through renal excretion.\(^{38}\) In further support for the technology, MSNs in the form of C-dots (Cornell dots) have been approved by US FDA for stage I clinical trial.\(^{42}\) Specific functionalization of the nanoparticles to enhance targetability to specific cell populations can expand the use of MSNs to efficient delivery of drugs to CSCs.

Here we identify specific phenotypic features of breast CSCs and utilize these features to design nanoparticles for efficient delivery and therapeutic efficacy of stem cell inhibitors. We demonstrate that Notch signaling is required for self-renewal of breast CSCs and for estrogen independent growth in vitro and in vivo, where it provides resistance toward estrogen-targeted therapies. We further show that Notch drives glycolytic metabolism and induces glycolytic switch in cancer cells. Intriguingly, we demonstrate that the breast CSCs display enhanced glucose uptake as compared to normal breast cancer cells. Utilizing these CSC features, we functionalized MSNs, carrying Notch inhibitors, with glucose analogues to efficiently deliver Notch signaling inhibitors to CSCs. Our data show that the functionalized particles target and are internalized by CSCs, and that the particles reduce the CSC pool and suppress tumor growth in vitro and in vivo in the chick embryo chorioallantoic- and murine xenograft-models.

RESULTS

Notch signaling induces cancer stem cells and enhances tumor growth

Notch signaling is activated by ligands on neighboring cells, inducing proteolytic processing of the receptor and releasing the intracellular domain (Notch intracellular domain) of the receptor, which translocates to the nucleus where it induces expression of downstream genes.\(^{11}\) To explore the influence of Notch signaling activity on breast tumor growth and on the cancer stem cell population, we used our previously engineered MCF7 breast cancer cells which express high, basal (normal), and reduced Notch activity by stable expression of constructs NICD1-GFP, GFP, and dominant-negative CSL-GFP.\(^{22}\) CSL is a key component of the Notch transcriptional complex. The cells are referred to as high-Notch, normal-Notch, and low-Notch cells, respectively.\(^{22}\) In line with our previous data,\(^{22}\) tumors initially developed from all three cell lines upon orthotopic xenotransplantation. At 9 weeks, the high-Notch cell-derived tumors showed dramatically enhanced tumor size coupled to increased proliferation compared with normalNotch cell as shown by expression of KI67 (Figure 1a,b). The high-Notch tumors exhibited increased expression of CD44, a widely used marker for CSCs (Figure 1a). CSCs can self-renew and sustain clonal growth. To test the capacity for self-renewal of high-Notch, normal-Notch, and low-Notch cells, we plated a very low number of cells from each group on low adherence plates in serum free medium supplemented with growth factors and followed formation of spheroids. Spheroids were subsequently collected, dissociated, and replated. high-Notch cells formed considerably higher numbers of, and bigger spheroids than normal-Notch, and could sustain several cycles of dissociation and replating, whereas the low-Notch cells were unable to form spheroids (Figure 1c). To further verify the CSC phenotype, we xenotransplanted 1,000 high-Notch, normal-Notch, and low-Notch cells in mice, as only CSCs have the capacity to initiate tumor growth when a very low number of cells is implanted. Tumors were observed in 3 of 5 mice transplanted with high-Notch, whereas normalNotch, and low-Notch cells did not form tumors within 3 months after transplantation. Histological analyses characterized the tumors as aggressive invasive carcinoma (Figure 1d).

Induced Notch activity reduces the amount of estrogen receptors in vitro and in vivo and maintains cell growth in the absence of estrogens

Notch has been implicated in resistance to therapy targeting hormone receptor signaling in breast cancer. MCF7 cells express the estrogen receptor (ER) and are dependent on estrogen for growth in vitro and in vivo. When high-Notch and normal-Notch MCF7 cells were grown in hormone depleted medium, 25% of normal-Notch cells died within 24 hours whereas the number of dead high-Notch cells was considerably lower, around 10% (Figure 2a). When tumors were immunolabeled for ER, high-Notch tumors displayed reduced amounts of receptors as compared to normal-Notch tumors (Figure 2b). To test if estrogen independence was associated with the cancer stem cell population, we tested the ability of the high-Notch CSCs to grow in vivo in the absence of estrogen supplements. Mice were gonadectomized to prevent physiological production of estrogen. We transplanted 25000 cells from dissociated spheroids in control and gonadectomized mice without estrogen supplement. α6 integrin expression in the spheroids confirmed the stem cell phenotype (Figure 2c). Tumors developed in four out of six mice transplanted with high-Notch CSCs. Initial tumor growth in gonadectomized mice without estrogen supplement was slower, than in the control group but at 7 weeks the tumors in the two groups were comparable in size (Figure 2d). Immunohistochemistry analyses of the tumors verified the cancer stem cell phenotype by the high expression of CD44 (Figure 2e). The tumors also expressed high levels of the cytokeratins 5/6, which are indicators of a basal like cancer phenotype, as well as the proliferation marker Ki67. Further, the tumors showed no expression of ERs (Figure 2e). This data indicate that the high-Notch CSCs are estrogen-independent and that Notch might promote resistance to estrogen targeted therapy in CSCs, in line with previous suggestions.\(^{26}\)

Glucose uptake is enhanced in cancer stem cells and cancer cells with elevated Notch activity

We have previously shown that Notch signaling promotes a glycolytic phenotype and enhances glucose uptake in breast cancer.\(^{22}\) To know if tumors with high Notch activity and enriched with CSCs also display enhanced glucose uptake in vivo we analyzed high-Notch and normal-Notch tumors with \(^{18}\)F-fluorodeoxyglucose Positron Emission Tomography (\(^{18}\)F-FDG PET). \(^{18}\)F-FDG PET revealed that tumors from high-Notch cells showed increased glucose uptake, compared to control tumors (Figure 3a), in line with our previous results.\(^{22}\) CSCs have been proposed to display a different metabolic phenotype than cancer cells. To assess glucose uptake in CSCs versus cancer cells we analyzed glucose uptake in adherent MCF7 and MDA-MB-231 breast cancer cells (adherent plate) and in CSC spheroids (spheroid plate) of the same cell lines using fluorescently labeled deoxyglucose (2NBDG). Cells
enriched for CSCs (spheroid plate) showed enhanced glucose uptake at both time points (Figure 3b,c). The difference in glucose uptake between cancer cells and CSCs was more pronounced in MCF7 cells, which can be explained by the fact that MCF7 cells per se are less glycolytic than MDA-MB-231 cells, whereas the CSC population in both cell lines is highly glycolytic. The difference in glycolytic profiles between MDA-MB-231 and lowNotch MCF7 cells was further confirmed by measuring the lactic acid production, i.e., extracellular acidification rate (ECAR) with Seahorse analyzer (Seahorse Bioscience) (Supplementary Figure S1). The difference in ECAR between the glucose-stimulated and oligomycin-treated conditions represents the spare glycolytic capacity, or glycolytic reserve, which was lower in lowNotch MCF7 than in MDA-MB-231 cells (Supplementary Figure S1). Cells with a low spare glycolytic capacity are likely to be more dependent on glycolysis, whereas cells with a higher glycolytic reserve capacity should be more tolerant of metabolic stress. The data is in line with our previous data where we show that blocking of Notch induces glucose addiction.22

Synthesis of glucose-decorated mesoporous silica nanoparticles for γ-secretase delivery

Our data show that Notch activation enhances glucose uptake and promotes aggressive hormone-independent tumor growth in vivo. As Notch signaling is critical for self-renewal of the CSCs, and as CSCs display a metabolic phenotype characterized by enhanced glucose uptake, we decided to utilize the metabolic phenotype to target the CSCs with Notch inhibitors. We aimed to enhance particle uptake in CSCs by utilizing the machinery for cellular import of glucose and using glucose derivatives (glucose and glucosamine and glucuronic acid) as affinity ligands on the MSNs. A schematic representation of the strategy is shown in Figure 4. MSNs were chosen due to their characteristic ability to carry, especially poorly water soluble, payload within their molecular-sized pores; and for their flexible surface functionalization possibilities.19–21 MSNs also have a previously proven ability for efficient delivery of GSIs, and for improved therapeutic efficacy in breast cancer.38 Further, our previous work has demonstrated that sugar decorated MSNs efficiently deliver apoptotic drugs to cancer cells in vitro.43

In that work, a hyperbranched surface polymer polyethyleminine (PEI) was used as linker between the MSNs and the glucose entity and compared to MSNs where the glucose was attached directly to the amino-functionalized particle surface without linker. Two different conjugation mechanisms were chosen to attach the glucose moiety to the hyperbranched PEI layer: direct attachment of glucose to the terminal amino groups via activation of free hydroxyl groups on the glucose molecule (MSN-PEI-Gluc) and activation of the −COOH groups of glucuronic acid with subsequent amine conjugation under aqueous (MSN-PEI-GAaq) or organic (MSN-PEI-GAorg) conditions. Here, we chose the same strategy for CSC

Figure 1 Notch activation enhances tumor growth. (a) Expression of the proliferation marker Ki67 and the stem cell marker CD44 in high Notch, medium Notch, and low Notch tumors at 9 weeks. low Notch shows mainly connective tissue. (b) Tumor diameter after xenografting in nude mice (n = 6 per group). (c) Primary and secondary sphere formation by high Notch, medium Notch, and low Notch. Light microscopy images were obtained with 20x magnification (d) Number of tumors formed/mice xenotransplanted with 1,000 high Notch, medium Notch, and low Notch cells. Histology of high Notch tumors resembles that of human grade 3 invasive carcinoma. Statistical significance is denoted by *P ≤ 0.05, **P ≤ 0.01.
Targeting Notch in Stem Cells With Nanoparticles

targeting, and continued to evaluate the particles for GSI delivery and therapeutic efficacy in vitro and in vivo. In addition, we chose an alternative strategy and linked glucosamine directly to carboxyl-functionalized particles via amide bond formation under mild conditions, after the carboxyl groups on the particles had been activated by conversion into NHS-esters. On all particles, the glucose moieties were accessible to interact with the glucose import systems of the cells. For characterization of the nanoparticles see Supplementary Figures S2–S5. All particles were highly monodisperse.

Glucose functionalized particles are internalized by cancer cells and cancer stem cells in vitro and in vivo

Next we evaluated the uptake of glucose-decorated particles in breast cancer cells by flow cytometry (FACS) analyses. MDA-MB-231 breast cancer cell were incubated with particles for 4 hours prior to FACS analyses. Direct attachment of glucose to PEI functionalized particles under organic (MSN-PEI-GAorg) conditions demonstrated the highest uptake among the particles with the hyperbranched PEI layer (Supplementary Figure S6a), and this particle was chosen for subsequent experiments. Hence, the subsequent analyses were performed using the following particles: particles with direct conjugation of glucose: MSN-G (control particles MSN); and particles with conjugation of glucose via a PEI linker: MSN-PEI-GAorg (control particles MSN-PEI). The corresponding particles without glucose-functionality were used as controls. Both sets of particles demonstrated a higher uptake.
Targeting Notch in Stem Cells With Nanoparticles

Figure 3 Tumors with hyperactive Notch signaling show enhanced glucose uptake. (a) Representative 18F-FDG PET images of mice 5 weeks after grafting with MCF7 cells engineered to express elevated or medium levels of Notch (tumor areas are circled). Scale bar 3E-1-5E0. (b,c) Cell populations enriched for cancer stem cells have enhanced glucose uptake. FACS analyses of naive MDA-MB-231 (b) and MCF7 (c) cells grown as adherent cells (adherent plate) or nonadherent spheroids (spheroid plate) incubated with fluorescently labeled deoxyglucose, 2NBDG, for 20 and 40 minutes. 2NBDG is displayed as mean fluorescent intensity. Cells grown as spheroids have enhanced glucose uptake. Shown is a representative graph of one out of three experiments.

Figure 4 Schematic presentation of the nanoparticle design. Elevated Notch signaling activity promotes the glycolytic phenotype; is important for self-renewal of cancer stem cells and supports estrogen-independent growth in estrogen positive breast cancer. Glycolytic cancer cells and cancer stem cells express glucose receptors on the surface. For efficient delivery of γ-secretase inhibitors (GSI), potent inhibitors of Notch activity, to glycolytic cancer stem cells we functionalized mesoporous silica particles with glucose moieties to target glucose receptors. The hydrophobic GSI is released from the particles and diffuses in the endosomal and cell membranes where it inhibits the γ-secretase, which is responsible for activating Notch signaling by proteolytic processing of the receptor. The glucose entities were linked to the particle to allow the glucose to interact with the glucose import systems, the glucose receptors, of the cells.
when they were functionalized with glucose entities (MSN-PEI versus MSN-PEI-GA, MSN versus MSN-G), although the increase was not significant for the particles lacking PEI and with direct glucose entity conjugation (MSN-G) (Figure 5a,b). However, it is well established that particles adsorbed to the outer cell membrane and not internalized by the cells could contribute to the fluorescent signal as determined by FACS. Therefore, the cellular uptake of the particles was further investigated by confocal microscopy (Figure 5c). Whereas MSN-G particles displayed an intracellular vesicular pattern, the nonglucose-tagged
MSN particles mostly accumulated in larger aggregates at the cell boarder, further supporting enhanced intracellular delivery by glucose functionalization. On the contrary, the PEI-functionalized particles displayed a more similar cellular distribution regardless the glucose functionalization (Figure 5c). Further, functionalization of particles with glucose moieties significantly enhanced uptake in MDA-MB-231 cancer cells as compared to the uptake in MCF10 mammary epithelial cells (Supplementary Figure S6b,c). Nonfunctionalized particles were internalized to the same degree by cancer and healthy cells. Of note, PEI-functionalization per se enhanced uptake in MDA-MB-231 cancer cells as compared to mammary epithelial cells MCF10 (Supplementary Figure S6b).

We next wanted to analyze uptake in CSCs. The CSC population was identified by aldehyde dehydrogenase-1 (ALDH1) activity in the cells using the ALDEFLUOR kit (Stem Cell Technologies, Cambridge, UK). Pharmacological inhibition of Notch by DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) for 24 hours prior to the analyses reduced the percentage of cells displaying ALDH1 activity, in line with the importance of Notch signaling for stem cell maintenance and renewal (Figure 5d and Supplementary Figure S7a). Both cancer cells and CSCs demonstrated efficient uptake of the MSN-PEI-G particles, with CSCs demonstrating increased uptake as compared to cancer cells (Figure 5e). CSCs also displayed enhanced uptake of the PEI-functionalized particles (MSN-PEI) (Figure 5f). By contrast, there was no significant increase in the uptake of the MSN-G particles in MDA-MB-231 CSCs as compared to cancer cells. However, in the less glycolytic MCF7 cells, where the CSC percentage of cells displaying ALDH1 activity, in line with the importance of Notch signaling for stem cell maintenance and renewal (Figure 5d and Supplementary Figure S7a). Both cancer cells and CSCs demonstrated efficient uptake of the MSN-PEI-G particles, with CSCs demonstrating increased uptake as compared to cancer cells (Figure 5e). CSCs also displayed enhanced uptake of the PEI-functionalized particles (MSN-PEI) (Figure 5f). By contrast, there was no significant increase in the uptake of the MSN-G particles in MDA-MB-231 CSCs as compared to cancer cells. However, in the less glycolytic MCF7 cells, where the CSC population demonstrated significantly enhanced glucose uptake as compared to the cancer cell population (Figure 3c), glucose functionalization increased the uptake of these particles in CSCs. Taken together, these data indicate that glucose targeting facilitates uptake in cancer cells and CSCs in accordance with the glycolytic phenotype of the cells.

To verify tumor targeting in vivo, we transplanted 3 × 10^6 glycolytic MDA-MB-231 cells orthotopically in the mammary glands in female NOD SCID mice. When the tumors reached ~100 mm^3, 20 mg/kg MSN or MSN-G particles, labeled with Atto647 for in vivo imaging, were injected in the tail vein. Both MSN and MSN-GA particles accumulated in the tumors (Figure 6a), albeit with different kinetics. For quantification of fluorescence intensity in the tumors, see Figure 6b.

**GSI loaded glucose-functionalized MSNs reduce the cancer stem cell pool in vivo**

To inhibit the Notch signaling pathway, we loaded the MSNs with the GSI, DAPT. The DAPT loading degree, µg DAPT per mg particles, for each set of particles was determined by high-performance liquid chromatography, and varied between 13 and 73 µg/mg between the different particles (Supplementary Figure S5). The ability of particles to inhibit the Notch signaling pathway and reduce the CSC pool was tested in vitro by treating adherent and spheroid MDA-MB-231 cells with DAPT and DAPT-loaded particles. Spheroids displayed higher ALDH1 activity in accordance with the enrichment of CSCs in spheroid cultures as compared to adherent cultures (Supplementary Figure S7a). Cells treated with free DAPT 5 or 50 µg/ml particles (note variable DAPT concentration) for 24 hours demonstrated reduced ALDH activity indicating a loss of CSC characteristics (Supplementary Figure S7a). The data demonstrated that inhibition of Notch by DAPT eliminates CSCs in vitro.

To verify the therapeutic efficacy and ability to target the CSCs in vivo, we utilized the chorioallantoic membrane (CAM) of a chick embryo as a tumor model.19 1 × 10^6 MDA-MB-231 cells were transplanted on the CAM on embryonic day 8, E8. From E8, particles were administered topically on the tumor once a day until day E13, when the tumor was explanted, weighed and dissociated, and analyzed by FACS. For the in vivo experiments, the particle concentration was adjusted such that the daily DAPT dose was 1 µg/tumor. Cancer cells and residual CAM cells were identified based on light scattering, whereas the CSCs were identified based on ALDH activity (Supplementary Figure S7b). The average number of events, i.e., number of cancer cells, CSCs and CAM cells per treatment is shown in Supplementary Figure S7c.

---

**Figure 6 Uptake of glucose-functionalized (GA) particles in MDA-MB-231 tumors in vivo.** (a) Accumulation of mesoporous silica particles (MSN) and MSN-GA particles in orthotopic MDA-MB-231 tumors in NSG mice after intravenous injection of 20 mg/kg particles. Tumors were implanted either in the left or the right mammary inguinal glands and distributed into two groups to receive either MSN or MSN-GA particles. Tumor accumulation was analyzed with Optix MX3 Small Animal Molecular Imager system (ART Inc) and the Optiview software (Versions 1.04 and 2.02; ART). The figure shows images of two mice injected with MSN particles (upper images) and two mice injected with MSN-GA particles (lower images) at the day of injection and the following day (24 hours). (b) The graphs show quantification of fluorescent intensity.
For further analyses, the number of cancer cells and CSCs per mg tissue was denoted. The analyses demonstrated a slight but significant decrease in number of cancer cells per mg tissue upon treatment with DAPT-loaded particles as compared to particles controls (Supplementary Figure S8). However, no significant difference in the number of CSCs was observed (Supplementary Figure S8). The data is in agreement with the insignificant difference in uptake of particles between cancer cells and CSCs (Figure 5).

A similar approach was used to evaluate therapeutic efficacy of the other set of particles where the glucose moiety was linked to the particle through PEI. Treatment with free DAPT or DAPT-loaded particles significantly reduced number of cancer cells per mg/tissue (Figure 7a). In addition, the number of CSCs per mg/tissue was significantly reduced in tumors treated with free DAPT, MSN-PEI-DAPT, MSN-PEI-GA_{org}-DAPT as compared to vehicle or nonloaded particle controls (Figure 7b). Interestingly, while the number of cancer cells/mg tissue was decreased as compared to the control for both non-loaded MSN-PEI and MSN-PEI-GA_{org}, the number of cancer stem cells, especially in the case of MSN-PEI-GA_{org} was higher than the control, which could suggest that these particles in their native state (without drug load) may boost the proliferation rate of the stem cells. These results are in line with in vivo results presented in Mamaeva et al.,\textsuperscript{38} where intravenous administration of empty MSN-PEI-FAM particles leads to enhanced Notch signaling, and enhanced tumor growth as compared to the control. Our data suggest that the surface charge of the particles (cationic/anionic) could be an important factor for influencing such background activity. In any case, free DAPT and DAPT-loaded particles reduced the number of CSCs. When the data were presented as fold reduction of CSCs as compared to the respective controls, it was evident that the glucose functionalized, DAPT-containing particles had the greatest effect on reducing CSCs. Taken together, we demonstrated that MSNs loaded with DAPT, especially when surface functionalized with glucose in combination with a cationic surface charge, efficiently targets and reduces the CSC population within a tumor.

**DISCUSSION**

Here, we demonstrate that Notch signaling is necessary for CSC self-renewal, therapy resistance and a metabolic switch to a glycolytic phenotype in breast cancer cells. We also show that CSCs display a glycolytic phenotype, and show enhanced glucose uptake as compared to cancer cells. Estrogen-independent breast cancer cells have higher Notch activity than estrogen-dependent cancer cells, and Notch signaling has been proposed to promote
targeted therapies such as Tamoxifen, the requirement of Notch in maintaining homeostasis in most tissues prevents the use of Notch inhibitors, and locally retained drug delivery is needed. Nanoparticles are well suited for targeted and controlled drug delivery. We have previously developed MSNs for tumor-targeted delivery of Notch inhibitors and demonstrated enhanced therapeutic efficacy and reduced side effects in preclinical tumor models of breast cancer. Here, we developed the platform further and utilized the specific metabolic profile of CSCs for efficient delivery of the Notch inhibitor DAPT to CSCs. DAPT-loaded bare and glucose-functionalized particles are efficiently internalized by CSC, reduce the CSC pool and inhibit tumor growth in vitro and in vivo.

Our data indicate that the surface charge of the MSNs influence uptake and targetability of the particles. Efficient targeting was observed for the glucose-tagged MSN-PEI particles, while a moderate targetability was observed for the anionic MSN-G particles. This difference is ascribed to the often observed more efficient uptake of cationic MSNs as compared to anionic MSNs, as an efficient electrostatically driven attachment to the negatively charged cell membrane is suggested to kinetically enhance uptake, both in the presence and absence of targeting ligands. It has been suggested that cationic particles can induce local nanoscale disruptions in the cell membrane, which enhances uptake. The enhanced uptake of cationic MSNs in CSCs as compared to that observed for cancer cells is in agreement with data reported by Chung et al., demonstrating higher uptake of MSNs by mesenchymal stem cells (MSCs) as compared to 3T3-L1 cells. Further, Lee et al. showed that MSCs exhibited a clearly more negative surface charge than differentiated cells. If this is true also for breast CSCs, this would explain the enhanced uptake of the cationic particles by these cells, and the more efficient DAPT delivery observed for the PEI-functionalized cationic particles as compared to the anionic counterparts. We do further not exclude the contribution of a more efficient retention of drug in the PEI-coated particles, where PEI could act as a so-called molecular gate, leading to more efficient intracellular drug delivery. As the particle diameters in the two cases are relatively similar, we do exclude particle size differences as the main reason for this observation. We also observed a higher number of CSCs in the tumors treated with nonloaded strongly cationic particles, which suggests that surface charge may be crucial for the effect of particles on stem cell self renewal and proliferation. This notion is in line with data in Chung et al. demonstrating that there is a cationic charge threshold above which proliferation is induced. This effect was not observed for particles with moderately cationic or anionic surface charge, and not in DAPT-loaded particles where drug release and effect coincide with particle degradation. Thus, our results in combination with other studies suggest that the MSN surface charge is indeed a decisive factor for stem cell proliferation rate, and care should be taken to not use too strongly cationic MSNs when aiming for cancer therapy-related applications. We can also relate this enhanced proliferation rate to the enhanced Notch levels induced by high concentrations of empty cationic particles demonstrated by us. Therefore, nanoparticle-influences on Notch levels are suggested to be useful evaluation criteria in vitro in future nanoparticle developments aiming at CSC-targeted therapies. A moderately cationic surface charge is suggested to be optimal, as the targetability was clearly enhanced for the cationic particles as compared to the anionic particles. However, the anionic glucose-functionalized MSNs were demonstrated to accumulate in the tumor area immediately after injection in the mouse model, and the particles were retained in the tumor area 1 day postinjection. Control particles void of glucose, on the other hand, showed a very low level of early tumor accumulation, but were observed to accumulate in the tumor area with time. These results demonstrate the value of glucose-functionalization also for the anionic MSN particles, although the level of targetability was limited in vitro. To which extent the early accumulation of MSN-G particles in the tumor area in vivo can be related to different extents of opsonization or to active targeting of the MSN-G particles in comparison to the control particles remains to be evaluated in future studies.

Our approach presents dual targeting of CSCs utilizing both the dependence of a specific stem cell pathway, Notch, for CSC function, and the specific metabolic profile of CSC to develop an efficient drug delivery platform for cancer treatment with a specific focus on eliminating the CSC population. The glycolytic phenotype of cancer cells have long been utilized for PET imaging and diagnostics in cancer, but has yet to be employed in targeted cancer stem cell therapy in the clinic although attempts to target cancer cell metabolisms has gained tremendous interest and several approaches are currently pre-clinically and clinically evaluated. We demonstrate that the CSCs also display a unique metabolic profile, which can be used to enhance therapeutic efficacy by targeting and eliminating the CSC pool. We demonstrate successful targeting and elimination of CSCs achieved by elucidation of molecular pathways necessary for CSC survival and resistance, and the identification of specific characteristics of CSCs and by developing a nanoparticle platform to target these characteristics of CSCs. Our data demonstrate that combining in depth understanding of CSC biology, and the development of drug delivery platforms has the potential to open up new possibilities for therapeutic intervention and enhance the success of current treatments.

**MATERIALS AND METHODS**

**Cell culture.** The cells used to generate stable cell lines were purchased from ATCC (Manassas, VA) and validated in 2009. The stable cell lines were generated at Karolinska Institute and at Turku Centre for Biotechnology. Naïve MDA-MB-231 and MCF7 cells used were purchased in 2010 and 2013 from ATCC. Human breast cancer cell lines MCF7 (including stable and inducible cell lines) and MDA-MB-231 were grown in Dulbecco’s
modified eagle's medium (Sigma D6171) supplemented with 10% fetal calf serum, L-glutamine, 25,000 units penicillin/25 mg streptomycin, nonessential amino acids, and sodium pyruvate. Spheroid cells were cultured on bacterial plates and were grown in Dulbecco’s modified eagle’s medium supplemented with 25 ng/ml basic fibroblast growth factor, 25 ng/ml epithelial growth factor, 1 x B-27, 1 mmol L-glutamine, and 25,000 units penicillin/25 mg streptomycin. Stable cell lines were selected with puromycin (1 µg/ml). Notch activity was blocked by addition of 5 µg/ml γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyler ester (DAPT; Calbiochem). Inducible Tet-on cell lines designated MCF7-EGFP and MCF7-N1ΔEGFP were induced by addition of 1 µg/ml doxycyclin. For particle handling and analyses of cellular uptake, see ref. 36.

Glucose uptake. Glucose uptake was measured using 2-NBDG (2-[(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] fluorescent probes (Invitrogen). MCF-7 cells were incubated in medium containing 100 µmol/l probe for 20 minutes. Cells were then washed twice in phosphate-buffered saline (PBS), trypsinized, pelleted, and resuspended in PBS followed by flow cytometry analysis using BD FACSCalibur running BD CellQuest PRO v.5.1.1 (BD Biosciences, Heidelberg, Germany).

**Supplementary Materials and Methods.**

**Tumor xenografts.** Animal experiments were conducted in accordance with the Institutional animal care policies of the University of Turku and Åbo Akademi University and/or approved by the Norwegian Animal Research Authority and performed in accordance with The European Convention for the Protection of Vertebrates Used for Scientific Purposes. Optical imaging studies (see Supplementary Data) were performed on female NOD/SCID IL2rγ−/− mice (Vivarium, University of Bergen). For additional information, refer to Supplementary Materials and Methods.

**Histological analysis and immunohistochemistry.** Paraffin embedding, sectioning, and hematoxylin–eosin staining was performed in the Department of Pathology and Forensic Medicine, University of Turku (special thanks to Sinikka Collanus). Immunohistochemistry was carried out with standard techniques, using commercial antibodies for Ki-67, CD44, CK5/6, ER and secondary antibody (Dako Cytomation EnVision System Copenhagen, Denmark). The reaction products were visualized applying DAB solution (Dako Cytomation Liquid DAB Substrate Chromogen System). Sections were then counterstained with Mayer’s hematoxylin. Negative controls were obtained by omission of the primary antibody. A board-certified pathologist reviewed slides in blind.

**Chicken chorioallantoic membrane assay.** Fertilized eggs are provided by Munax Oy (Laitila, Finland) and placed oval end upwards in a thermostat incubator at 37 °C, for 6 days before applying experimental treatment. Small holes are opened on the pointed end. 1 million cultured cells are mixed with 10 µl cell media and 10 µl Matrigel and xenografted on top of the CAM. Xenografted tumors are incubated for 24 hours to attach to the membrane. Nanoparticle concentration is adjusted to acquire 1 µg DAPT for each treatment, and particles are sonicated in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid for 20 minutes before topical treatment, performed over 6 days. The tumors are collected on day 13 and washed with PBS at +4 °C. In vivo fluorescence imaging was performed after the 6 days.

**Supplementary Material**

**Figure S1.** Glycolysis was analyzed in dnCSL MCF7 and untreated MDA-MB-231 by measuring the extracellular acidification rate (ECAR) by use of a Seahorse XF96 Analyzer.

**Figure S2.** TEM images and overview of nanoparticle characteristics.

**Figure S3.** Schematic presentation of synthesis and characteristics of MSN-G.

**Figure S4.** Thermogravimetric analyses and optical analyses of fluorescent particles.

**Figure S5.** Quantification of the DAPT load in particles.

**Figure S6.** Uptake of glucose functionalized particles in MDA-MB-231 cancer cells and cancer stem cells, in healthy MCF10 mammary epithelial cells and in vivo.

**Figure S7.** Notch inhibition by DAPT eliminates the cancer stem cell population in vitro and in vivo.

**Figure S8.** MDA-MB-231 cells were transplanted on CAM and treated with DAPT loaded or empty particles.

**Data**

**Materials and methods**

**Acknowledgments**

This work was supported by the Academy of Finland grants 218062 (C.S.) 260599 (E.O., D.D., and J.M.R.) and Sigrid Juselius Foundation and Cancer Society of Finland (C.S.). R.N. was supported by the Swedish Cultural Foundation of Finland, Svensk-österbottniska samfundet, K. Albin Johannsson foundation, Liv och Hålsa Foundation. S.L. was supported by the Swedish Cultural Foundation of Finland, Magnus Ehrnrooth Foundation, Waldemar von Frenckell Foundation, K. Albin Johannsson foundation, the Swedish Research Council, EU (ITN NotchIT). M.B. was supported by Ulm University funding. E.M. was supported by the Norwegian Cancer Society (grant number 732200), the Western health board of Norway (Helse Vest; grant numbers 911182 and 911789), and the Bergen Research Foundation. The Cell Imaging Core at the Turku Center of Biotechnology is thanked for access to infrastructure and technical assistance. The in vivo fluorescence imaging was performed at the Molecular Imaging Centre (MIC), University of Bergen, and Mireia Mayoral Safont is thanked for her technical assistance. The authors declare that they have no conflict of interest.

**References**

1. Al-Hajj, M, Wicha, MS, Benito-Hernandez, A, Morrison, SJ and Clarke, MF (2003). Identification of human brain tumour initiating cells. *Proc Natl Acad Sci USA* **100**: 3983–3988.

2. Bonnet, D and Dick, JE (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* **3**: 730–737.

3. O’Brien, CA, Pollett, A, Gallinger, S and Dick, JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature** **445**: 106–110.

4. Reya, T, Morrison, SJ, Clarke, MF and Weissman, IL (2001). Stem cells, cancer, and cancer stem cells. *Nat Rev Cancer** **2**: 105–111.

5. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. *Nature** **432**: 396–401.

6. Dean, M, Fojo, T and Bates, S (2005). Tumour stem cells and drug resistance. *Nat Rev Cancer** **5**: 275–284.

7. LaBarge, MA (2010). The difficulty of targeting cancer stem cell niches. *Cancer Res* **70**: 3121–3129.

8. Plaks, V, Kong, N and Werb, Z (2015). The cancer stem cell niche: how essential is the niche in regulating stemness of tumors? *Cell Stem Cell** **16**: 225–238.

9. Shibuya, K, Okada, M, Suzuki, S, Seino, M, Seino, S, Takeda, H et al. (2015). Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumour-initiating capacity of cancer stem cells. *Oncotarget** **6**: 651–661.
10. Ntziachristos, P, Lim, JS, Sage, J and Atlantis, I (2014). From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 25: 318–334.
11. Hori, K, Sen, A and Artavanis-Tsakonas, S (2013). Notch signaling at a glance. J Cell Sci 126(Pt 10): 2135–2140.
12. Reedijk, M, Pinnaduwage, D, Dickson, BC, Mulligan, AM, Zhang, H, Bull, SB et al. (2008). JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111: 439–448.
13. Takebe, N, Miele, L, Harris, PJ, Jeong, W, Bando, H, Kahn, M et al. (2015). Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 12: 445–464.
14. Muellner, MK, Uras, IZ, Gapp, BV, Kerzendorfer, C, Smida, M, Lechermann, H et al. (2011). A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 7: 787–793.
15. Dong, Y, Li, A, Wang, J, Weber, JD and Michel, LS (2010). Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70: 5465–5474.
16. Martz, CA, Ottina, KA, Singleton, KR, Jasper, JS, Wardell, SE, Peraza-Penton, A et al. (2014). Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal 7: ra121.
17. Abravanel, DL, Belka, GK, Pan, PC, Pant, DC, Collins, MA, Sterner, CJ et al. (2015). Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest 125: 2484–2496.
18. Pannuti, A, Foreman, K, Rizzo, P, Osipo, C, Golde, T, Osborne, B et al. (2009). Targeting Notch signaling in cancer treatment. Pharmaco Ther 139: 95–110.
19. Rizzo, P, Miao, H, D’Souza, G, Osipo, C, Song, LL, Yun, J et al. (2008). Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68: 5226–5235.
20. Sahlgren, C, Gustafsson, MV, Jin, S, Poellinger, L and Lendahl, U (2008). Notch signaling mediates hypha-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105: 6392–6397.
21. Mani, SA, Guo, W, Liao, MJ, Eaton, EN, Ayyanan, A, Zhou, AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.
22. Landor, SK, Mutvei, AP, Mamaeva, V, Jin, S, Busk, M, Borra, R et al. (2011). Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc Natl Acad Sci USA 108: 18814–18819.
23. Takebe, N, Nguyen, D and Yang, SX (2014). Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 139: 140–149.
24. Andersson, ER and Lendahl, U (2014). Therapeutic modulation of Notch signaling—are we there yet? Nat Rev Drug Discov 13: 357–378.
25. van Es, JH, van Gijn, ME, Riccio, O, van den Born, M, Vooijs, M, Beug, H et al. (2005). Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenosomas into goblet cells. Nature 435: 959–963.
26. Rizzo, P, Osipo, C, Foreman, K, Golde, T, Osborne, B and Miele, L (2008). Rational targeting of Notch signaling in cancer. Oncogene 27: 5124–5131.
27. Yancopoulos, GD, Davis, LS, Gale, NW, Glotzer, M, Nusse, R (2005). From Drosophila to mammalian development: the Hedgehog story. Genes Dev 19: 2133–2164.
28. Wiegand, M and Kaltschmidt, M (2010). Targeting notch signaling pathways in cancer stem cells: a novel strategy for cancer therapy. Clin Cancer Res 16: 3141–3152.
29. Espinoza, I and Miele, L (2013). Notch inhibitors for cancer treatment. Pharmacol Ther 139: 95–110.
30. Vitaglione, A, Foreman, K, Rizzo, P, Osipo, C, Golde, T, Osborne, B and Miele, L (2009). Targeting notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer. Adv Enzyme Regul 49: 134–141.
31. Karaman, DS, Desai, D, Senthilkumar, R, Johansson, EM, Rätz, N, Ödén, M et al. (2012). Shape engineering vs organic modification of inorganic nanoparticles as a tool for enhancing cellular internalization. Nano Lett 13: 11179–11184.
32. Chen, J, Hessler, JA, Putchakalya, K, Panama, BK, Khan, DP, Hong, S et al. (2009). Cationic nanotubes induce nanoscale disruption in living cell plasma membranes. Nano Lett 9: 689–702.
33. Chung, TH, Wu, SH, Yao, M, Lu, CW, Lin, YS, Hung, Y et al. (2007). The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 28: 2599–2606.
34. Lee, IC, Wang, JH, Lee, YT and Young, TH (2007). Development of a useful technique to discriminate anterior cruciate ligament cells and mesenchymal stem cells—the application of cell electrophoresis. J Biomed Mater Res A 82: 230–237.
35. Galluzzi, L, Kepp, O, Vander Heiden, MG and Kroemer, G (2013). Metabolic targets for cancer therapy. Nat Rev Drug Discov 12: 829–846.
36. Galluzzi, O and Vander Heiden, MG (2011). Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671–684.